Epigenetic Diversity in Glioblastoma Academic Background Glioblastoma is the most common primary malignant brain tumor. Despite decades of research, its prognosis remains extremely poor, with an average survival of only 14 months after diagnosis. The significant heterogeneity of glioblastoma is one of the main reasons for the slow progress in its t...

Microglia and Macrophages in Glioblastoma Academic Background Glioblastoma (GBM) is the most common primary malignant tumor of the central nervous system, characterized by high invasiveness and lethality. Despite standard treatments such as surgery, chemotherapy, and radiotherapy, the survival rate of patients remains extremely limited, with a medi...

Pathological Validation of MRI Tumor Habitats in Glioblastoma Background Introduction Glioblastoma (GBM) is a highly malignant brain tumor characterized by significant heterogeneity and invasiveness. Due to its complex tumor microenvironment (TME), traditional imaging methods struggle to accurately distinguish different tumor regions, such as the t...

Crossing the Blood–Brain Barrier: Study on Adipose-Derived Stem Cells as Carriers for Pro-Apoptotic Oncolytic Myxoma Virus in the Treatment of Murine Glioblastoma Background and Objective Glioblastoma (GBM) is among the most invasive and aggressive brain tumors, characterized by high recurrence rates and poor prognosis. Despite multimodal intervent...

Inhibitory Fcγ Receptor Deletion Enhances CD8 T Cell Stemness, Increasing Anti-PD-1 Therapy Responsiveness in Glioblastoma Background and Objectives of the Study Glioblastoma (GBM) is an aggressive central nervous system tumor with poor prognosis, and the median survival of patients is only 14.6 months. Despite the significant efficacy of immune ch...